SPRY UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

Faruqi & Faruqi is investigating potential securities-law claims against ARS Pharmaceuticals (NASDAQ: SPRY) and notes that a federal securities class action has been filed. Investors who purchased or acquired ARS securities between March 9, 2026 and June 24, 2026 have until October 5, 2026 to seek appointment as lead plaintiff.

Analysis

This is not a fundamental catalyst by itself; plaintiff-firm notices are largely solicitation-driven and often follow a sharp drawdown. The investable issue is whether the underlying complaint identifies an omitted operational, regulatory, safety, reimbursement, or commercialization fact that forces a guidance reset. Without the complaint and the company’s prior disclosures, expected legal expense is unlikely to justify a directional view, but the litigation can increase perceived governance risk and cap multiple recovery for the next 1-3 months.

SPRY is likely to trade on any independently corroborated allegation rather than on the lead-plaintiff deadline. A credible restatement, product-label change, adverse regulatory correspondence, or reduced revenue/launch guidance would create a second leg lower because biotech investors will reprice both probability of commercial success and financing needs; absent those developments, a litigation-only selloff is more likely an opportunity for existing fundamental holders than a new short. The key contrarian point is that litigation headlines can create liquidity pressure in a small-cap biotech without changing enterprise value, making borrow cost and short interest more important than headline sentiment.

Key Decisions for Investors

• No new directional SPRY position solely on this notice; obtain the filed complaint, alleged corrective disclosures, cash runway, and latest guidance before assigning fundamental downside.
• Set a 1-3 month alert for an SPRY guidance reduction, regulatory disclosure, restatement, or cash-runway deterioration; any of these would validate a short or put-spread thesis, while their absence weakens the litigation-overhang case.
• For existing long exposure, reduce position size rather than hedge aggressively into the October 5 procedural deadline; that date is not an operating catalyst. Reassess after the next earnings release and any company response to the allegations.
• Avoid naked short exposure until borrow availability/cost and short interest are verified. If litigation-driven weakness materially exceeds the move implied by an underlying earnings or regulatory revision, consider a tactical long only with a defined stop below the post-disclosure low.